Edition:
India

Versartis Inc (VSAR.OQ)

VSAR.OQ on NASDAQ Stock Exchange Global Select Market

2.03USD
20 Jul 2018
Change (% chg)

$0.03 (+1.25%)
Prev Close
$2.00
Open
$2.00
Day's High
$2.03
Day's Low
$2.00
Volume
8,719
Avg. Vol
89,660
52-wk High
$22.10
52-wk Low
$1.35

Chart for

About

Versartis, Inc. is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company's first indication for somavaratan is pediatric GHD. The Company may develop... (more)

Overall

Beta: 2.44
Market Cap(Mil.): $94.42
Shares Outstanding(Mil.): 35.63
Dividend: --
Yield (%): --

Financials

BRIEF-Versartis Q1 Loss Per Share $0.25

* CASH, CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS WERE $74.7 MILLION AS OF MARCH 31, 2018 Source text for Eikon: Further company coverage:

09 May 2018

BRIEF-Versartis Says Board Approved Plan Of Termination To Eliminate A Number Of Positions Effective Oct 20, 2017

* VERSARTIS SAYS IN OCTOBER 2017, BOARD APPROVED PLAN OF TERMINATION TO ELIMINATE A NUMBER OF POSITIONS EFFECTIVE OCT 20, 2017 - SEC FILING

09 May 2018

BRIEF-Versartis Q4 Earnings Per Share $0.87

* VERSARTIS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

02 Mar 2018

BRIEF-Advent Life Sciences Reports 4.5 Pct Passive Stake In Versartis Inc

* ADVENT LIFE SCIENCES LLP REPORTS A 4.5 PERCENT PASSIVE STAKE IN VERSARTIS, INC. AS OF DEC 31, 2017 - SEC FILING Source text - http://bit.ly/2EuDXO8 Further company coverage:

08 Feb 2018

Earnings vs. Estimates